Filtered By:
Drug: Fortamet

This page shows you your search results in order of relevance. This is page number 15.

Order by Relevance | Date

Total 6511 results found since Jan 2013.

Statins for women with polycystic ovary syndrome not actively trying to conceive
CONCLUSIONS: The evidence for all main outcomes of this review was of very low certainty. Due to the limited evidence, we are uncertain if statins compared with placebo, or statins plus metformin compared with metformin alone, improve resumption of menstrual regularity. The trial evaluating statin plus OCP versus OCP alone reported neither of our primary outcomes. No other studies reported resumption of spontaneous ovulation. We are uncertain if statins improve hirsutism, acne severity, or testosterone. All trials that measured adverse events reported no significant differences between the groups.PMID:37462232 | PMC:PMC103...
Source: Cochrane Database of Systematic Reviews - July 18, 2023 Category: General Medicine Authors: Ting Xiong Eloise Fraison Eleni Kolibianaki Michael F Costello Christos Venetis Elena B Kostova Source Type: research

Hypoglycemic agents and incidence of pancreatic cancer in diabetic patients: a meta-analysis
Conclusion: Sulfonylureas and insulin may increase the incidence of pancreatic cancer in diabetic patients, with varying effects observed among different ethnicities (Asian and Western). Due to significant heterogeneity across studies, further interpretation of the relationship between hypoglycemic agents and pancreatic cancer incidence in diabetic patients requires well-adjusted data and better-organized clinical trials.PMID:37497113 | PMC:PMC10366383 | DOI:10.3389/fphar.2023.1193610
Source: Cancer Control - July 27, 2023 Category: Cancer & Oncology Authors: Zimo Zhao Xinyi He Yan Sun Source Type: research

JAMIA: Reduction in medication errors in hospitals due to adoption of computerized provider order entry systems
This study appears reasonable for inclusion in a meta-analysis, although ideally there might have been accounting for possible influence of non-intervention (computer)-related pre-post interval changes.  The transition to CPOE, training, increased awareness, etc. can influence results, especially short term. Included study #7 (footnote 16):Error reduction in pediatric chemotherapy: computerized order entry and failure modes and effects analysis. Arch Pediatr Adolesc Med 2006;160:495–8.Before-and-after study from 2001 to 2004. After CPOE deployment, daily chemotherapy orders were less likely to have improper dos...
Source: Health Care Renewal - March 3, 2013 Category: Health Medicine and Bioethics Commentators Tags: Mark D Spranca AMIA Melanie R Wasserman medication error Lauren EW Olsho David C Radley healthcare IT risks Sarah J Shoemaker Bethany Bradshaw JAMIA healthcare IT benefits CPOE Source Type: blogs

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Combination with Metformin.
CONCLUSION: In summary, DPP-4 inhibitors play a vital role in the treatment of diabetes. They have relatively limited adverse effects, especially regarding hypoglycemia. DPP-4 inhibitors in combination with metformin are generally well tolerated and are available as combination products to reduce pill burden and enhance compliance. The limitations to DPP-4 inhibitors are the lack of outcomes data and more limited HbA1c lowering than other medications currently approved for the treatment of type 2 diabetes. However, as previously stated, thiazolidinediones, glinides, sulfonylureas, pramlinitide, and GLP-1 agonists are all q...
Source: Advances in Therapy - April 15, 2013 Category: Drugs & Pharmacology Authors: Fass AD, Gershman JA Tags: Adv Ther Source Type: research

Complementing Insulin Therapy to Achieve Glycemic Control.
CONCLUSION: GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT2 inhibitors improve glycemic control when combined with insulin. They also have low propensity for weight gain and hypoglycemia and so may be preferred treatment options for insulin combination when compared with traditional therapies. PMID: 23797471 [PubMed - as supplied by publisher]
Source: Advances in Therapy - June 25, 2013 Category: Drugs & Pharmacology Authors: Barnett AH Tags: Adv Ther Source Type: research

GLP‐1 receptor agonists vs. DPP‐4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?
ConclusionGLP‐1RAs provide superior glycaemic control and weight loss vs. DPP‐4 inhibitors in patients with T2D. DPP‐4 inhibitors may sometimes be preferred to a GLP‐1RA if weight is not a concern, oral administration is a desirable feature or when a GLP‐1RA cannot be tolerated.
Source: International Journal of Clinical Practice - February 1, 2014 Category: Internal Medicine Authors: S. Brunton Tags: Review Article Source Type: research

The pharmacogenetics of type 2 diabetes: a systematic review.
CONCLUSIONS We found evidence of pharmacogenetic interactions for metformin, sulfonylureas, repaglinide, thiazolidinediones, and acarbose consistent with their pharmacokinetics and pharmacodynamics. While high-quality controlled studies with prespecified analyses are still lacking, our results bring the promise of personalized medicine in diabetes one step closer to fruition. PMID: 24558078 [PubMed - in process]
Source: Diabetes Care - February 22, 2014 Category: Endocrinology Authors: Maruthur NM, Gribble MO, Bennett WL, Bolen S, Wilson LM, Balakrishnan P, Sahu A, Bass E, Kao WH, Clark JM Tags: Diabetes Care Source Type: research

The Near Horizon for Visions of Slowing Aging
The mainstream of the aging research community, or at least that fraction of it that is interested at all in increasing healthy longevity by intervening in the aging process, is almost entirely focused on the use of drugs to alter metabolism to slightly slow the onset of frailty and ill-health in later life. There isn't even much effort to find new drugs: candidates are largely existing drugs. Many of these researchers exclusively discuss compression of morbidity, the goal of extending healthy life without extending overall life span. There is still an aversion in many circles to any talk of extending overall human life sp...
Source: Fight Aging! - October 21, 2014 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs

Influence of LH and high-density lipoprotein cholesterol (HDL-C) on metformin response in women with polycystic ovary syndrome
Conclusion In weight-matched PCOS subjects, laboratory markers might predict the metformin response. Higher levels of basal LH and lower levels of HDL-C are correlated with a positive response to metformin treatment in PCOS subjects.
Source: European Journal of Obstetrics and Gynecology and Reproductive Biology - October 12, 2014 Category: OBGYN Source Type: research

Metformin: Repurposing Opportunities for Cognitive and Mood Dysfunction.
Conclusions: Available evidence does not provide a robust signal for improvement in cognition in either mood disorder or T2DM samples. Notwithstanding, it is premature to label metformin as a "no-go" agent for further testing and development for cognitive dysfunction. A well designed, proof-of-concept trial of metformin investigating its possible cognitive effects in mood disorders is therefore warranted. PMID: 25470390 [PubMed - as supplied by publisher]
Source: CNS and Neurological Disorders Drug Targets - November 30, 2014 Category: Drugs & Pharmacology Authors: Ying MA, Maruschak N, Mansu RR, Carvalho AF, Cha DS, McIntyre RS Tags: CNS Neurol Disord Drug Targets Source Type: research

Effect comparison of metformin with insulin treatment for gestational diabetes: a meta-analysis based on RCTs
Conclusion Metformin can significantly reduce several adverse maternal and neonatal outcomes including PIH rate, incidence of hypoglycemia and NICU, thus it may be an effective and safe alternative or additional treatment to insulin for GDM women.
Source: Archives of Gynecology and Obstetrics - December 30, 2014 Category: OBGYN Source Type: research

Dulaglutide: The Newest GLP-1 Receptor Agonist for the Management of Type 2 Diabetes.
CONCLUSIONS: Dulaglutide is the fifth GLP-1 RA approved for T2D in the United States. It is an attractive option because it is dosed once-weekly, provides A1C lowering similar to liraglutide, weight reduction similar to exenatide, and has an adverse effect profile similar to exenatide and liraglutide. PMID: 25565404 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - January 6, 2015 Category: Drugs & Pharmacology Authors: Thompson AM, Trujillo JM Tags: Ann Pharmacother Source Type: research

Predictors of response in initial users of metformin and sulphonylurea derivatives: a systematic review
ConclusionsSeveral demographic and clinical factors were identified as possible predictors of response to metformin and sulphonylurea, but the number of studies with sufficient quality was small. Generally, early treatment seems important for achieving better glycaemic outcomes.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - January 13, 2015 Category: Endocrinology Authors: D. P. Martono, R Lub, H. J. Lambers Heerspink, E. Hak, B. Wilffert, P. Denig Tags: Systematic Review or Meta‐analysis Source Type: research

The Pharmacologic Treatment of Type 2 Diabetes: Oral Medications.
CONCLUSION: There are now 9 distinct oral pharmacologic classes and a variety of insulin and noninsulin injectable medications available for the treatment of type 2 diabetes. Metformin remains the first-line treatment option for most patients. When considering options for alternative or additional treatment, prescribers must weigh the benefits and risks using individual patient characteristics. PMID: 25667196 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - February 9, 2015 Category: Drugs & Pharmacology Authors: Tran L, Zielinski A, Roach AH, Jende JA, Householder AM, Cole EE, Atway SA, Amornyard M, Accursi ML, Shieh SW, Thompson EE Tags: Ann Pharmacother Source Type: research

Interventions for hirsutism (excluding laser and photoepilation therapy alone).
CONCLUSIONS: Treatments may need to incorporate pharmacological therapies, cosmetic procedures, and psychological support. For mild hirsutism there is evidence of limited quality that OCPs are effective. Flutamide 250 mg twice daily and spironolactone 100 mg daily appeared to be effective and safe, albeit the evidence was low to very low quality. Finasteride 5 mg daily showed inconsistent results in different comparisons, therefore no firm conclusions can be made. As the side effects of antiandrogens and finasteride are well known, these should be accounted for in any clinical decision-making. There was low quality evidenc...
Source: Cochrane Database of Systematic Reviews - April 28, 2015 Category: Journals (General) Authors: van Zuuren EJ, Fedorowicz Z, Carter B, Pandis N Tags: Cochrane Database Syst Rev Source Type: research